Dose dependent nanoparticle albumin bound paclitaxel + pembrolizumab alters the immune micro environment in a esophageal homograft mouse model.

Esophageal cancer has remained a therapeutic challenge despite the advancements in targeted therapy and immunotherapy. This study investigated the mechanism by which neoadjuvant pembrolizumab combined with carboplatin and varying dosages of albumin-b…

Preview only. Read the full abstract at the source